Overview

Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis

Status:
Terminated
Trial end date:
2018-10-29
Target enrollment:
Participant gender:
Summary
Study to evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-051 administered for 12 weeks in subjects with moderate to severe plaque psoriasis.
Phase:
Phase 2
Details
Lead Sponsor:
Akros Pharma Inc.